Essentials
• Cognitive disorders are increasing and vascular risk factors play a role in this.
• We performed a nested case control study of hemostasis biomarkers and cognitive impairment (CI).
• Higher baseline fibrinogen, factor VIII and D-dimer were related to incident CI over 3.5 years.
• Adjusted for other risk factors, 2+ abnormal markers (but not single ones) led to higher risk.
Summary. Background: Vascular risk factors are associated with cognitive impairment, a condition that imposes a substantial public health burden. We hypothesized that hemostasis biomarkers related to vascular disease would be associated with the risk of incident cognitive impairment. Methods: We performed a nested case-control study including 1082 participants with 3.5 years of follow-up in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a longitudinal cohort study of 30 239 black and white Americans aged ≥ 45 years. Participants were free of stroke or cognitive impairment at baseline. Baseline D-dimer, fibrinogen, factor VIII and protein C levels were measured in 495 cases who developed cognitive impairment during follow-up (based on abnormal scores on two or more of three cognitive tests) and 587 controls. Results: Unadjusted odds ratios (ORs) for incident cognitive impairment were 1.32 (95% confidence interval [CI] 1.02-1.70) for D-dimer > 0.50 lg mL À1 , 1.83 (95% CI 1.24-2.71) for fibrinogen > 90th percentile, 1.63 (95% CI 1.11-2.38) for FVIII > 90th percentile, and 1.10 (95% CI 0.73-1.65) for protein C < 10th percentile. There were no differences in associations by race or region. Adjustment for demographic, vascular and health behavior risk factors attenuated these associations. However, having at least two elevated biomarkers was associated with incident cognitive impairment, with an adjusted OR of 1.73 (95% CI 1.10-2.69). Conclusion: Elevated D-dimer, fibrinogen and FVIII levels were not associated with the occurrence of cognitive impairment after multivariable adjustment; however, having at least two abnormal biomarkers was associated with the occurrence of cognitive impairment, suggesting that the burden of these biomarkers is relevant.
Introduction
Dementia and cognitive dysfunction are prevalent, devastating and costly conditions [1] that are increasing in frequency as the population ages [2] . Although many risk factors for dementia have been identified in recent decades [1] , the underlying mechanisms for many of these associations are unknown. Biological processes that lead to dementia probably begin long before clinical signs of cognitive dysfunction are apparent. Identification of biomarkers of brain health may help in the detection of disease at an earlier stage, and in identifying targets that can be modified to slow or reverse disease progression. Contributions of vascular disease and its risk factors to cognitive impairment and dementia are increasingly evident [3] . As they are also vascular risk markers, biomarkers associated with hypercoagulable states might also relate to cognitive impairment. Hemostasis biomarkers that have been investigated in this regard include fibrinogen, D-dimer, factor VII, FVIII, prothrombin fragment 1 + 2, von Willebrand factor (VWF), and plasminogen activator inhibitor-1 (PAI-1). There are few prospective studies on the relationship between these biomarkers and cognitive impairment or dementia, and they have reported inconsistent associations. The most extensively studied biomarker is fibrinogen. Six studies reported direct associations of higher fibrinogen levels with incident cognitive impairment (ICI), Alzheimer's disease (AD), vascular dementia (VaD), or cognitive decline [4] [5] [6] [7] [8] [9] , and one study found no association with dementia [10] . One study reported an association of higher D-dimer levels with VaD but not with AD [10] , two reported an association with declines in cognitive test scores [6, 11] , and two more reported no association with cognitive decline or dementia [4, 5] . FVIII has been investigated in only one study, and was associated with VaD but not with other forms of dementia or cognitive impairment [4] . A meta-analysis of D-dimer, fibrinogen, FVII, prothrombin fragment 1 + 2, VWF and PAI-1 in relation to cognitive decline and dementia [12] reported small but potentially important associations, especially between D-dimer and VaD. Little research has been directed at the anticoagulant proteins. Low protein C levels were associated with stroke risk in one study [13] , but we are not aware of studies on protein C and cognitive function. Racial differences in hemostasis biomarker levels have been identified, with blacks having a more procoagulant profile than whites [14, 15] . Only one study of hemostasis markers and the risk of cognitive decline included a large number of African Americans [11] .
There are regional differences in ICI in the USA [16] ; regions with a higher risk of cognitive impairment overlap with the 'stroke belt', which comprises eight southeastern states (AL, AR, NC, SC, GA, TN, MI, LA) with increased risks of stroke incidence and mortality [17] . Whether abnormal levels of hemostasis biomarkers might mediate the geographical difference in ICI is unknown.
We examined the associations of D-dimer, fibrinogen, FVIII and protein C with ICI in a large national cohort of black and white Americans. We investigated whether associations differed by race, and whether differences in the levels of these biomarkers contributed to any of the higher ICI risk in the stroke belt. We previously reported that a higher FVIII level was associated with ICI in this study in the context of ABO blood group, finding a minimally adjusted odds ratio (OR) of 1.24 (95% confidence interval [CI] 1.10-1.38) per standard deviation (SD) higher FVIII level [18] , and here we extend that analysis with more detail and the inclusion of other biomarkers.
Methods

Subjects
The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study has been described in detail elsewhere [19] . In brief, the study enrolled 30 239 Americans aged ≥ 45 years from 2003 to 2007. Participants were 58% white and 42% black, 45% male and 55% female, and 56% from the stroke belt region and 44% from the other 40 contiguous states. Participants were recruited by random selection from a commercially available nationwide list. Exclusion criteria were race other than black or white, Hispanic ethnicity, active treatment for cancer, medical conditions that would prevent longterm participation, cognitive impairment as judged by the telephone interviewer, residence in or inclusion on a waiting list for a nursing home, or inability to communicate in English. After verbal consent was obtained, a medical history, including cardiovascular risk factors, was collected by computer-assisted telephone interview. Thereafter, subjects participated in an in-home examination, which included height, weight and blood pressure measurements, a resting electrocardiogram (ECG), a medication inventory, and fasting blood and urine samples. Methods were approved by the institutional review boards of all participating institutions, and all participants provided written informed consent.
The REGARDS study includes a two-level longitudinal telephone-based assessment of cognitive function: (i) the Six-Item Screener (SIS) [20] , added to the baseline assessment in 2003 and then performed annually; and (ii) a three-test cognitive battery, introduced in 2006 and administered at 2-year intervals. This battery includes the Animal Fluency Test (AF) [21] , Word List Learning (WLL) and Word List Recall (WLR) from the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) battery [22] . The SIS is a brief screening tool with three immediate recall items and three temporal orientation items. A score of ≤ 4 represents cognitive impairment [16, 23] . The AF is a measure of verbal fluency in which the participant names as many animals as possible in 60 s. WLL and WLR consist of a 10-item, three-trial word list learning and recall task. The WLL score is the sum of immediate recall across the three trials, with a range of 0-30. After the last learning trial, the participant is asked non-cognitive interview questions for 5 min, and is then asked to provide a free recall of the word list, resulting in the WLR score, with a range of 0-10.
Covariates collected included age, race (black or white), sex, education (lower than high school, high school, some college, or college and above), yearly income (< $20 000, $20 000-34 999, $35 000-74 999, ≥ $75 000, or refused), region (stroke belt or non-stroke belt), cigarette smoking (never, past, or current), alcohol intake (none, moderate [≤ 14 drinks per week for men; ≤ 7 drinks per week for women] or heavy [> 14 drinks per week for men; > 7 drinks per week for women]), physical activity level (any weekly exercise versus none), history of transient ischemic attack, coronary artery disease (CAD), defined as myocardial infarction by self-report or ECG or history of coronary revascularization (stenting, coronary artery bypass surgery, or percutaneous transluminal coronary angioplasty), atrial fibrillation (self-reported or by ECG), left ventricular hypertrophy (LVH) by ECG, body mass index (BMI) calculated from height and weight measurements, hypertension (systolic blood pressure of > 140 mmHg or diastolic blood pressure of > 90 mmHg on an average of two measurements, or self-reported use of hypertension medication), dyslipidemia (total cholesterol ≥ 240 mg dL À1 , LDL ≥ 160 mg dL self-reported use of diabetes medications). A C-reactive protein (CRP) level > 90th percentile was included as a covariate to control for inflammation. Aspirin, warfarin and statin use were determined by medication inventory. The presence of incident stroke was ascertained via telephone follow-up every 6 months with the Questionnaire for Verifying Stroke-free Status [24] , and verified by medical record review and adjudication by a panel of stroke experts. Stroke occurring after enrollment but prior to the most recent cognitive assessment was included as a covariate.
Nested case-control study
As previously described [18] , we adapted a REGARDS case-cohort study sample drawn in 2011, which included an 1104-person cohort sample, to develop a nested casecontrol study of ICI. Among 17 630 participants without prevalent stroke, without baseline cognitive impairment according to the SIS, and with sufficient follow-up cognitive domain testing at the time of case selection in 2011, we identified an ICI case group of 495 participants, as described in detail elsewhere [25] . Cases scored > 1.5 SD below age-adjusted, race-adjusted, sex-adjusted and education-adjusted predicted scores on at least two of the three cognitive domain tests in the most recently administered three-test cognitive battery (median follow-up of 3.5 years). From the 1104-person cohort random sample, to develop a control group, we applied the same exclusion criteria as for case selection, excluding 83 participants with prevalent stroke, 108 with cognitive impairment on the first SIS, 306 with insufficient cognitive testing to determine whether they developed ICI, and 20 who developed ICI, leaving 587 controls for this nested case-control study.
Laboratory analysis
Blood samples were collected at the baseline in-home visit. A draw tube containing 4.5 mmol L À1 EDTA, 0.15 KIU L À1 aprotinin, and 20 mol L À1 D-Phe-Pro-Argchloromethylketone (SCAT-1; Haematologic Technologies, Essex Junction, VT, USA), designed to prevent in vitro clotting activation [26, 27] , was included. This plasma was used for the current study. Samples were centrifuged for 10 min near participants' homes, and serum and plasma was shipped overnight to the University of Vermont core laboratory, where they were recentrifuged at 30 000 9 g min, and then stored at À 80°C. Case and control samples were analyzed together in random order so that technicians were blinded to their status. . Results above or below the detectable limit of the assay were recoded as at the detectable limit for statistical analysis. The validity of all assays performed on SCAT-1 plasma samples similarly processed and shipped overnight had been confirmed previously [28] . Biomarker results were missing for 5.8% of the cases and 5.2% of the controls, mainly because of lack of sample availability. Apolipoprotein E (ApoE) genotype was determined by TaqMan analysis of the two single-nucleotide polymorphisms rs429358 and rs4712 [29] . Haplotypes were reconstructed with the PHASE program [30] , with ambiguous haplotypes coded as their most likely outcome if the probability was > 85%. Cholesterol, glucose and CRP were previously measured in the entire REGARDS cohort [19, 31] .
Statistical analysis
Analyses were conducted with STATA 11.0 (StataCorp, College Station, TX, USA). Because of the stratified nature of the control group, analyses were probability weighted, and 95% CIs were calculated by use of a Taylor series with finite population correction. Weights were based on the total number of participants who were eligible to become cases (N = 17 630) and the probability of being selected for the cohort random sample for each stratum, given ICI case eligibility. Baseline characteristics were compared between cases and controls by the use of weighted Pearson chi-square tests (corrected for survey design with the second-order correction of Rao and Scott [32] and converted into an F-statistic). Among controls, median biomarker levels were compared between blacks and whites and between stroke belt residents and non-residents by the use of Wilcoxon rank-sum tests. Weighted logistic regression models were used to calculate ORs and 95% CIs of ICI for each biomarker, as an estimate of relative risk. Biomarkers were analyzed continuously, in quartiles, and as abnormal or normal, with abnornal levels being defined as those above the 90th percentile for FVIII and fibrinogen, below the 10th percentile for protein C, and above the clinically used cutpoint of 0.50 lg mL À1 for D-dimer. Percentile/ quartile cutpoints were calculated on the basis of the weighted distribution in the cohort random sample. We examined the burden of elevated biomarker levels by assessing the association of two or more versus fewer than two abnormal biomarkers with ICI. When examined continuously, all four hemostasis biomarker predictors violated the assumption of a linear relationship between log odds ICI and predictor. Log transformation or quadratic terms did not resolve this violation, so continuously expressed concentrations were not investigated further; instead, we used quartiles. Models were first carried out unadjusted, and then adjusted for demographics, health behaviors, vascular risk factors, the presence of one or more ApoE4 alleles, incident stroke, and baseline warfarin, aspirin and statin use. A biomarker 9 race interaction term was tested in each model, and, if this was significant, we stratified by race. Biomarker 9 region and biomarker 9 biomarker interaction terms were also examined. Because of concerns regarding colinearity, models were used with and without CRP as a covariate. A sensitivity analysis was conducted with exclusion of participants receiving warfarin at baseline. We planned a mediation analysis for any biomarker that was associated with both ICI and had adverse levels in the stroke belt; however, none of the biomarkers or the number of abnormal biomarkers met this criterion, and the analysis was not performed.
Participants with missing data on predictors or covariates were excluded from adjusted models, leaving 403 complete cases (82% of the total) and 521 complete controls (83% of the total). Participants missing data were similar to those included, except that they were more likely to have low income and diabetes (Table S1 ). Given the number of available cases and controls, and considering biomarker concentrations > 90th percentile as the risk factor, we had 80% power to detect an OR for ICI of 1.51.
Results
Weighted baseline characteristics of cases and controls are shown in Table 1 . Because of the demographically adjusted regression-based selection of ICI cases, cases and controls were similar in age, race, sex, and education. Cases were more likely to report lower income, current smoking, and abstention from alcohol, and had higher prevalences of diabetes, hypertension, LVH, CAD, elevated CRP levels, and obesity. Abnormal D-dimer, fibrinogen and FVIII levels, but not protein C levels, were more prevalent in cases than in controls. Other characteristics in Table 1 
0.43 lg mL À1 , P = 0.004) and protein C (66% versus 121%, P < 0.001) levels than non-users, but similar fibrinogen and FVIII levels. In the time between enrollment and the most recent cognitive assessment, 21 participants survived a stroke. Eight were controls and 13 were cases (P = 0.04 for difference). Table 2 shows the OR of ICI for each hemostasis biomarker expressed in quartiles and as abnormal levels. Abnormal levels of D-dimer, fibrinogen and FVIII were all associated with ICI in unadjusted analysis. None of the hemostasis biomarkers was associated with ICI in fully adjusted analysis. Sensitivity analysis excluding CRP as a covariate and excluding participants who reported warfarin use did not substantively change the results (data not shown).
In evaluation of differences in the associations of hemostasis biomarkers with ICI risk by race, only the association of FVIII > 90th percentile with ICI appeared to differ by race (P-value for interaction of 0.06 in the fully adjusted model; other P-values for interaction of > 0.40 in the unadjusted and adjusted models). Although the adjusted ORs of ICI for FVIII > 90th percentile versus lower were 1.76 (95% CI 0.88-3.51) in whites and 1.05 (95% CI 0.43-2.58) in blacks, this finding is probably spurious, because, for FVIII in the top versus the bottom quartile, the adjusted ORs were 2.31 (95% CI 0.95-5.57) in blacks and 0.83 (95% CI 0.43-1.58) in whites (P-value for interaction of 0.92).
Two-predictor models including hemostasis biomarkers and one covariate at a time were used to identify which factors were confounders of the associations of hemostasis markers with ICI. For fibrinogen and FVIII, income, diabetes and CRP > 90th percentile each decreased the b-coefficient for both biomarkers by at least 10%, as did coronary heart disease for FVIII. Income, diabetes, alcohol and BMI each decreased the b-coefficient for D-dimer by at least 10%. In addition to individual confounders, we assessed groups of demographic, health behavior or vascular risk factors in separate models (Table 3) .
Considering D-dimer, fibrinogen, and FVIII (but not protein C, as it was not associated with ICI), participants with two or more abnormal biomarkers versus those with fewer than two abnormal biomarkers had ORs of ICI of 2.17 (95% CI 1.39-3.37) in unadjusted analysis, and 1.90 (95% CI 1.04-3.51) in fully adjusted analysis. Most of the participants with two or more abnormal biomarkers had elevated D-dimer (96%) levels; 49% had elevated fibrinogen levels, and 55% had elevated FVIII levels. The levels of these biomarkers were modestly correlated with each other (Spearman correlations of 0.31-0.33). The interactions between D-dimer and FVIII and between Ddimer and fibrinogen were not statistically significant on the multiplicative scale (P = 0.20 and P = 0.36, respectively).
Residence in the stroke belt was associated with higher odds of ICI in unadjusted (OR 1.63, 95% CI 1.25-2.11) and fully adjusted (OR 1.60, 95% CI 1.17-2.40) analyses. Median D-dimer, fibrinogen, protein C, FVIII and two or more elevated hemostasis biomarkers did not differ by region; consequently, differences in biomarker levels were not mediators of this regional difference in ICI (data not shown). Furthermore, there were no differences in the associations of biomarkers with risk of ICI by region (all P > 0.10).
Discussion
In this prospective study, elevated levels of D-dimer, fibrinogen, and FVIII, but not low levels of protein C, were modestly associated with ICI risk in unadjusted models. Associations did not differ by race or region. Other demographic and vascular risk factors accounted for the higher ICI risk with these biomarkers, as associations were attenuated in fully adjusted models.
Despite the lack of association of individual biomarkers with ICI risk, elevated levels of two or more biomarkers increased the risk of ICI nearly two-fold in fully adjusted analyses. This essentially involved participants with elevated D-dimer plus at least one other elevated biomarker, suggesting that the burden of perturbed procoagulant balance relevant to ICI risk cannot be detected with individual biomarkers. Our findings were similar to those of Gallacher et al. [4] , who reported that concurrent elevations of fibrinogen, FVIII and PAI-1 were associated with a hazard ratio of 2.97 (95% CI 1.38-4.56) for incident VaD.
Residence in the stroke belt was associated with ICI in this analysis, as was shown in a previous report in the REGARDS study using a global cognitive test score [16] . The absence of higher levels of biomarkers in the stroke belt and no biomarker effect modification by region indicate that hemostasis biomarkers do not mediate the excess ICI risk in the stroke belt. Despite limited literature suggesting that a lower protein C level is associated with stroke [13] , including in the REGARDS study [33] , we did not see an association of a lower protein C level with ICI.
Fibrinogen is a marker of inflammation and a hypercoagulable state [34] , and inflammation and hemostasis are tightly linked. Others reported that the association of fibrinogen and cognitive decline was stronger for VaD than for AD [4, 7, 10] , suggesting mechanisms related to infarcts and neurostructural damage caused by atherosclerosis. However, in vitro and mouse model evidence suggests that b-amyloid (Ab), the hallmark protein of AD, interacts with fibrinogen to form abnormal fibrin structures [35, 36] . These abnormal fibrin-Ab structures are deposited in the neurovasculature and are resistant to degradation [37] , causing neurovascular inflammation and damage contributing to ICI in AD patients, and they can be inhibited pharmacologically in a mouse model [38] .
Whether circulating levels of fibrinogen can reflect this biology is unclear.
The only prior study of FVIII and ICI, to our knowledge, reported a higher VaD risk [4] . Several studies investigated the association of the related protein VWF with ICI, with mainly null findings [4, 6, 10] . FVIII and VWF are closely correlated, as FVIII binds VWF while it is circulating in blood, and rapidly degrades when not bound. We did not measure VWF, because field processing and shipping methods in the REGARDS study affected the validity of VWF assays [28] .
Previous prospective studies investigating D-dimer had mixed results, some reporting an association with VaD [6, 10] and ICI [11] , and others finding no association [4, 5] .
We demonstrated multiple confounders of the association of hemostasis markers with ICI. Individually, income, diabetes and CRP had large impacts. The D-dimer association was confounded by health behaviors and vascular risk factors. FVIII was most confounded by vascular risk factors. The association of fibrinogen and ICI remained apparent until demographic, health behavior and vascular risk factors were all included in the model. Incremental decreases in most of the ORs with stepwise addition of covariates suggest that many of the covariates have a small but ultimately cumulative effect on the relationship between hemostasis biomarkers and ICI.
Differences between our findings and those of previous studies may be attributable to which covariates were accounted for. Many prospective studies reporting associations of fibrinogen with dementia or ICI did not adjust for socioeconomic factors [5, [7] [8] [9] . Stott et al., who observed differences in rates of decline on several cognitive tests with higher D-dimer and fibrinogen level [6] adjusted for education, but not income, which was a strong correlate of ICI in our study, even when other socioeconomic variables, including education, were accounted for. Gallacher et al. [4] adjusted for social class, and reported that fibrinogen, FVIII and PAI-1 were associated with incident VaD, but not with non-VaD. Their study included only men within the Caerphilly locality in South Wales, UK, which may also explain the differences from our results.
The differences between our findings and other published literature may also be attributable to differences in definitions of the outcome or predictors. We could not determine the etiology of ICI in our study or classify it into clinical diagnoses. As some of the previous research identified associations of hemostasis biomarkers with VaD only [4, 7, 10] , it is possible that this subgroup was too small within our ICI cases to identify individual biomarker associations. We studied biomarker levels as continuous, categorical and dichotomous predictors. Only biomarkers above an established clinically significant cutpoint (> 0.50 lg mL -1 for D-dimer) or at levels ≥ 90th percentile of the distribution showed an association with ICI. Other previously published studies analyzed continuous variables [5, [7] [8] [9] 11] , tertiles [6] , quintiles [7, 10] or zscore [4] predictors. Limitations of this study include loss of statistical power in adjusted analyses because of missing covariates. Although complete cases did not differ substantially from incomplete cases,~17% of the cases and controls were omitted from some of the fully adjusted analyses. We suspect that this limitation would only bias our findings to the null by reducing statistical power. We had 80% power to detect an OR for ICI of 1.51 in those with biomarker levels > 90th percentile in adjusted analysis. The OR point estimates for fibrinogen and FVIII in these models were 1.40 and 1.19, respectively. If these are the true effect sizes, a larger sample size is needed to confirm this finding. The results are generalizable to blacks and whites in the USA, but might not apply to other groups. Finally, the findings regarding risk related to the presence of two or more elevated biomarkers should be interpreted cautiously, given the lack of associations of individual biomarkers with ICI in the adjusted models, and as residual confounding because of unmeasured factors might partly explain this association. Strengths of this study are the inclusion of blacks and whites from a national cohort study and well-characterized vascular risk factors. The nested case-control design and baseline blood samples allowed prospective assessment of the associations of biomarkers with ICI, reducing the likelihood of reverse causality explaining positive findings. Also, cases and controls were free from stroke and cognitive impairment as determined with a screening tool at baseline. As stroke may be in the causal pathway between elevated hemostasis marker levels and ICI, we included participants who survived incident stroke and evaluated its effect in adjusted analyses.
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